Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 6/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 6/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 6/20 | 0.56 |
| ▸ | GRIK5 | Q16478 | 6/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | DUT | P33316 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Willardiine SCHEMBL438494 | 1.00 | GRIA1 (0.56) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL666953 | 0.86 | GRM5 (0.50) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL3635924 | 0.81 | DUT (0.57) | KMT2AKDM4EPKMDUTALDH1A1 | |
| SCHEMBL7136481 | 0.81 | PKM (0.56) | PKMDUTALDH1A1LMNA | |
| SCHEMBL5001166 | 0.78 | DUT (0.51) | GRIA1GRIA2GRIA4GRIK5CYP1A2 | |
| SCHEMBL667078 | 0.78 | PKM (0.61) | PKMDUTALDH1A1LMNA | |
| SCHEMBL14478216 | 0.78 | PKM (0.61) | PKMDUTALDH1A1LMNA | |
| SCHEMBL23873265 | 0.78 | PKM (0.60) | PKMDUTALDH1A1LMNA | |
| SCHEMBL4311546 | 0.77 | DUT (0.50) | KMT2AKDM4EPKMDUTALDH1A1 | |
| SCHEMBL5000786 | 0.77 | DUT (0.50) | KMT2AKDM4EPKMDUTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303549-B2 | Methods of treating or inhibiting onset of Huntington's disease | UNIVERSITY OF ROCHESTER (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220062378-A1 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | UNIVERSITY OF COPENHAGEN (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3810184-A2 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | University of Rochester (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2008097546-A2 | COMPOUNDS THAT INHIBIT CHOLINESTERASE | COLUCID PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008031888-A2 | CONDENSED PYRIMIDINONES ACTIVE ON GLUTAMATERGIC RECEPTORS | CAMPIANI GIUSEPPE (IT) | 2008-03-20 | — | — | WO | disclosed |
| US-20070275959-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | SENTION, INC. | 2007-11-29 | — | — | US | disclosed |
| CN-1898201-A | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | SENTION INC (US) | 2007-01-17 | — | — | CN | disclosed |
| EP-1689704-A2 | CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND RELEASE PHARMACOLOGICALLY ACTIVE AGENTS | CoLucid Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005042475-A2 | CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND RELEASE PHARMACOLOGICALLY ACTIVE AGENTS | SENTION, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096387-A1 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | SENTION, INC. (US) | 2005-05-05 | — | — | US | disclosed |
| US-20050037445-A1 | Oncology drug innovation | POULSEN, HANS SKOVGAARD (DK) | 2005-02-17 | — | — | US | disclosed |
| EP-1446501-A2 | METHODS FOR IDENTIFICATION OF CANCER CELL SURFACE MOLECULES AND CANCER SPECIFIC PROMOTERS, AND THERAPEUTIC USES THEREOF | Buadbo APS (DK) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003000928-A2 | METHODS FOR IDENTIFICATION OF CANCER CELL SURFACE MOLECULES AND CANCER SPECIFIC PROMOTERS, AND THERAPEUTIC USES THEREOF | BUADBO APS (DK) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | GRIA1 4078/4885GRIA2 3900/4885GRIA4 3805/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | GRIA1 4078/4885GRIA2 3900/4885GRIA4 3805/4885 |
| US-20070275959-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | ACHE, BCHE, CHAT | GRIA1 1432/4885GRIA2 1522/4885GRIA4 1222/4885 |
| US-20050096387-A1 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | ACHE, BCHE, CHAT | GRIA1 1565/4885GRIA2 1427/4885GRIA4 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.